We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.15%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$171M
AUM Growth
-$23M
Cap. Flow
+$1.07M
Cap. Flow %
0.63%
Top 10 Hldgs %
90.76%
Holding
44
New
4
Increased
4
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$1.3M
2
AXGN icon
Axogen
AXGN
+$826K
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$732K
4
VYGR icon
Voyager Therapeutics
VYGR
+$326K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$297K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.92M
2
MRK icon
Merck
MRK
+$640K
3
PRTA icon
Prothena Corp
PRTA
+$235K

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Energy 2.75%
3 Industrials 0.47%
4 Consumer Staples 0.28%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$77.6M 45.52%
744,051
-17,000
-2% -$1.92M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$57.2M 33.54%
218,380
– –
VRML
3
DELISTED
Vermillion, Inc.
VRML
$4.75M 2.79%
2,462,933
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.4B
$4.07M 2.38%
52,400
– –
EQT icon
5
EQT Corp
EQT
$30.7B
$2.41M 1.41%
77,705
– –
AAAP
6
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$1.8M 1.05%
22,000
– –
OXFD
7
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.78M 1.04%
127,303
+50,000
+65% +$732K
OVV icon
8
Ovintiv
OVV
$16.2B
$1.76M 1.03%
26,460
– –
CORT icon
9
Corcept Therapeutics
CORT
$9.83B
$1.72M 1.01%
95,000
– –
QDEL icon
10
QuidelOrtho
QDEL
$1.13B
$1.69M 0.99%
38,975
– –
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$320M
$1.34M 0.78%
88,000
+20,000
+29% +$297K
CFRX
12
DELISTED
ContraFect Corporation
CFRX
$1.15M 0.67%
1,419
– –
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$1.06M 0.62%
25,000
– –
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
$1.03M 0.6%
+45,229
New +$1.3M
AXGN icon
15
Axogen
AXGN
$2.1B
$991K 0.58%
+35,000
New +$826K
SIEN
16
DELISTED
Sientra, Inc.
SIEN
$890K 0.52%
6,330
– –
SITO
17
DELISTED
SITO MOBILE, LTD
SITO
$806K 0.47%
120,000
– –
VCYT icon
18
Veracyte
VCYT
$4.57B
$776K 0.45%
118,767
– –
VYGR icon
19
Voyager Therapeutics
VYGR
$184M
$714K 0.42%
43,000
+19,000
+79% +$326K
MASI
20
DELISTED
Masimo
MASI
$678K 0.4%
8,000
– –
WMGI
21
DELISTED
Wright Medical Group Inc
WMGI
$666K 0.39%
30,000
– –
BIOL
22
DELISTED
Biolase, Inc.
BIOL
$548K 0.32%
103
– –
PXD
23
DELISTED
Pioneer Natural Resource Co.
PXD
$519K 0.3%
3,000
– –
YTEN
24
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$479K 0.28%
282
+46
+19% +$124K
TSRO
25
DELISTED
TESARO, Inc.
TSRO
$431K 0.25%
5,200
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Birchview Capital held 44 positions worth $171M, down 12% from $194M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q4 2017 filing shows 4 new, 4 increased, 1 reduced and 2 closed positions. Its largest new stake was Soleno Therapeutics: 45,229 shares worth $1.03M. The largest sale was Celgene Corp, an estimated $1.92M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q4 2017 buy was Soleno Therapeutics: 45,229 shares worth $1.03M.
  • Birchview Capital added most to Oxford Immunotec Global PLC Ordinary Shares in Q4 2017, an estimated $732K increase.
  • Birchview Capital's biggest Q4 2017 reduction was Celgene Corp, cutting an estimated $1.92M.
  • Birchview Capital fully exited Merck in Q4 2017, selling an estimated $640K.
  • Birchview Capital's ten largest holdings make up 91% of its $171M portfolio in Q4 2017.
  • Birchview Capital opened 4 new positions and closed 2 in Q4 2017.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $171M.

Based on Birchview Capital's 13F filing for Q4 2017, filed 2 Feb 2018.